相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs
Taira Ninomaru et al.
THORACIC CANCER (2021)
Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol
Kazuya Nishii et al.
THORACIC CANCER (2021)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
V. A. Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2020)
Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice
Katsuyuki Hotta et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
Maximilian J. Hochmair et al.
FUTURE ONCOLOGY (2019)
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
D. Westover et al.
ANNALS OF ONCOLOGY (2018)
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations
Tomoki Tamura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
Eiki Ichihara et al.
Oncotarget (2018)
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403
Naohiro Oda et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
Kenichiro Kudo et al.
MOLECULAR ONCOLOGY (2017)
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience
Kenichiro Kudo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience
Naohiro Oda et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI
Akito Hata et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience
Yuka Kato et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Review of EGFR TKls in etastatic NSCLC, including ongoing trials
Barbara Melosky
FRONTIERS IN ONCOLOGY (2014)
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives
Raffaele Costanzo et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Percutaneous Lung Biopsy: Technique, Efficacy, and Complications
Ronald S. Winokur et al.
SEMINARS IN INTERVENTIONAL RADIOLOGY (2013)
The international epidemiology of lung cancer - Geographical distribution and secular trends
Danny R. Youlden et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
分享论文
